These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

500 related items for PubMed ID: 28033332

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Combination renin-angiotensin system blockade with the renin inhibitor aliskiren in hypertension.
    Doulton TW, MacGregor GA.
    J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):185-9. PubMed ID: 19617273
    [Abstract] [Full Text] [Related]

  • 23. Aliskiren reduces morning blood pressure in hypertensive patients with diabetic nephropathy.
    Takenaka T, Nobe K, Okayama M, Kojima E, Nodaira Y, Sueyoshi K, Hoshi H, Watanabe Y, Takane H, Suzuki H.
    Clin Exp Hypertens; 2012 Dec; 34(4):243-8. PubMed ID: 22559034
    [Abstract] [Full Text] [Related]

  • 24. Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trial.
    Heerspink HJ, Ninomiya T, Persson F, Brenner BM, Brunel P, Chaturvedi N, Desai AS, Haffner SM, Mcmurray JJ, Solomon SD, Pfeffer MA, Parving HH, de Zeeuw D.
    Diabetes Obes Metab; 2016 Feb; 18(2):169-77. PubMed ID: 26511599
    [Abstract] [Full Text] [Related]

  • 25. Aliskiren for the treatment of essential hypertension under real-life practice conditions: design and baseline data of the prospective 3A registry.
    Zeymer U, Dechend R, Deeg E, Kaiser E, Senges J, Pittrow D, Schmieder R, 3A Registry Investigators.
    Int J Clin Pract; 2012 Mar; 66(3):251-61. PubMed ID: 22321062
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis.
    Vejakama P, Thakkinstian A, Lertrattananon D, Ingsathit A, Ngarmukos C, Attia J.
    Diabetologia; 2012 Mar; 55(3):566-78. PubMed ID: 22189484
    [Abstract] [Full Text] [Related]

  • 28. Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE).
    Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Nicolaides M, Richard A, Xiang Z, Armbrecht J, Pfeffer MA, ALTITUDE Investigators.
    J Renin Angiotensin Aldosterone Syst; 2012 Sep; 13(3):387-93. PubMed ID: 22333485
    [Abstract] [Full Text] [Related]

  • 29. Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes.
    Persson F, Rossing P, Schjoedt KJ, Juhl T, Tarnow L, Stehouwer CD, Schalkwijk C, Boomsma F, Frandsen E, Parving HH.
    Kidney Int; 2008 Jun; 73(12):1419-25. PubMed ID: 18337712
    [Abstract] [Full Text] [Related]

  • 30. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K.
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [Abstract] [Full Text] [Related]

  • 31. Combination therapy with aliskiren versus ramipril or losartan added to conventional therapy in patients with type 2 diabetes mellitus, uncontrolled hypertension and microalbuminuria.
    Imbalzano E, Scarpelli M, Mandraffino G, Creazzo M, Lizio G, Trapani G, Dattilo G, Dalbeni A, Tomasello C, Sardo MA, Saitta A.
    J Renin Angiotensin Aldosterone Syst; 2015 Dec; 16(4):956-64. PubMed ID: 25070350
    [Abstract] [Full Text] [Related]

  • 32. Urinary renin and angiotensinogen in type 2 diabetes: added value beyond urinary albumin?
    Persson F, Lu X, Rossing P, Garrelds IM, Danser AH, Parving HH.
    J Hypertens; 2013 Aug; 31(8):1646-52. PubMed ID: 23743807
    [Abstract] [Full Text] [Related]

  • 33. Effect of direct renin inhibitor monotherapy on proteinuria in overt diabetic nephropathy.
    Silaratana S, Sumransurp S, Duangchana S, Tasanarong A.
    J Med Assoc Thai; 2012 Jan; 95 Suppl 1():S18-23. PubMed ID: 23964439
    [Abstract] [Full Text] [Related]

  • 34. [The future of renin inhibition].
    Uresin AY, Baran E.
    Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():32-8. PubMed ID: 20019475
    [Abstract] [Full Text] [Related]

  • 35. Efficacy and Safety of Dual Blockade of the Renin-Angiotensin-Aldosterone System in Diabetic Kidney Disease: A Meta-Analysis.
    Feng Y, Huang R, Kavanagh J, Li L, Zeng X, Li Y, Fu P.
    Am J Cardiovasc Drugs; 2019 Jun; 19(3):259-286. PubMed ID: 30737754
    [Abstract] [Full Text] [Related]

  • 36. Long-term antihypertensive effects of aliskiren, a direct renin inhibitor, in chronic hemodialysis patients.
    Ishimitsu T, Ohta S, Ohno E, Takahashi T, Numabe A, Okamura A, Ohba S, Hashimoto A, Matsuoka H.
    Ther Apher Dial; 2013 Oct; 17(5):524-31. PubMed ID: 24107281
    [Abstract] [Full Text] [Related]

  • 37. Therapeutic approaches in lowering albuminuria: travels along the renin-angiotensin-aldosterone-system pathway.
    Heerspink HJ.
    Adv Chronic Kidney Dis; 2011 Jul; 18(4):290-9. PubMed ID: 21782135
    [Abstract] [Full Text] [Related]

  • 38. Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial.
    Heerspink HJ, Persson F, Brenner BM, Chaturvedi N, Brunel P, McMurray JJ, Desai AS, Solomon SD, Pfeffer MA, Parving HH, de Zeeuw D.
    Lancet Diabetes Endocrinol; 2016 Apr; 4(4):309-17. PubMed ID: 26774608
    [Abstract] [Full Text] [Related]

  • 39. Time course of antiproteinuric effect of aliskiren in arterial hypertension associated with type 2 diabetes and microalbuminuria.
    Fogari R, Mugellini A, Zoppi A, Preti P, Maffioli P, Perrone T, Derosa G.
    Expert Opin Pharmacother; 2013 Mar; 14(4):371-84. PubMed ID: 23414196
    [Abstract] [Full Text] [Related]

  • 40. Efficacy of add-on therapy of aliskiren to an angiotensin II receptor blocker on renal outcomes in advanced-stage chronic kidney disease: a prospective, randomized, open-label study.
    Soji K, Doi S, Nakashima A, Sasaki K, Kawai T, Aoki A, Kyuden Y, Fujiwara K, Yokoyama Y, Masaki T.
    Clin Exp Nephrol; 2015 Aug; 19(4):631-8. PubMed ID: 26293451
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.